Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 230.39 Billion KRW | 15.81% |
| 2022 | 198.93 Billion KRW | 11.9% |
| 2021 | 177.77 Billion KRW | 3.54% |
| 2020 | 171.7 Billion KRW | 7.87% |
| 2019 | 159.17 Billion KRW | 2.92% |
| 2018 | 154.66 Billion KRW | 4.54% |
| 2017 | 147.95 Billion KRW | 4.65% |
| 2016 | 141.37 Billion KRW | -2.77% |
| 2015 | 145.39 Billion KRW | 20.45% |
| 2014 | 120.71 Billion KRW | 15.54% |
| 2013 | 104.47 Billion KRW | -2.56% |
| 2012 | 107.22 Billion KRW | -2.57% |
| 2011 | 110.05 Billion KRW | 4.13% |
| 2010 | 105.68 Billion KRW | 6.34% |
| 2009 | 99.38 Billion KRW | 6.96% |
| 2008 | 92.91 Billion KRW | 16.01% |
| 2007 | 80.09 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 68.11 Billion KRW | 7.06% |
| 2024 Q2 | 63.61 Billion KRW | 3.26% |
| 2024 Q1 | 61.61 Billion KRW | 5.52% |
| 2023 FY | 230.39 Billion KRW | 15.81% |
| 2023 Q1 | 55.54 Billion KRW | 6.49% |
| 2023 Q4 | 58.38 Billion KRW | -0.77% |
| 2023 Q3 | 58.84 Billion KRW | 2.11% |
| 2023 Q2 | 57.62 Billion KRW | 3.76% |
| 2022 Q2 | 48.57 Billion KRW | -0.56% |
| 2022 Q1 | 48.84 Billion KRW | 8.58% |
| 2022 Q4 | 52.15 Billion KRW | 5.67% |
| 2022 Q3 | 49.36 Billion KRW | 1.62% |
| 2022 FY | 198.93 Billion KRW | 11.9% |
| 2021 Q3 | 44.97 Billion KRW | 5.58% |
| 2021 FY | 177.77 Billion KRW | 3.54% |
| 2021 Q1 | 45.22 Billion KRW | 2.3% |
| 2021 Q2 | 42.59 Billion KRW | -5.82% |
| 2021 Q4 | 44.98 Billion KRW | 0.03% |
| 2020 Q3 | 43.33 Billion KRW | 2.87% |
| 2020 Q2 | 42.12 Billion KRW | 0.19% |
| 2020 FY | 171.7 Billion KRW | 7.87% |
| 2020 Q1 | 42.04 Billion KRW | 8.94% |
| 2020 Q4 | 44.2 Billion KRW | 2.02% |
| 2019 Q4 | 38.59 Billion KRW | -5.35% |
| 2019 Q2 | 40.51 Billion KRW | 3.14% |
| 2019 Q1 | 39.28 Billion KRW | 6.45% |
| 2019 FY | 159.17 Billion KRW | 2.92% |
| 2019 Q3 | 40.77 Billion KRW | 0.63% |
| 2018 Q1 | 38.12 Billion KRW | 0.58% |
| 2018 FY | 154.66 Billion KRW | 4.54% |
| 2018 Q4 | 36.9 Billion KRW | -7.32% |
| 2018 Q3 | 39.81 Billion KRW | 0.01% |
| 2018 Q2 | 39.81 Billion KRW | 4.45% |
| 2017 Q4 | 37.89 Billion KRW | 1.75% |
| 2017 FY | 147.95 Billion KRW | 4.65% |
| 2017 Q2 | 36.68 Billion KRW | 1.54% |
| 2017 Q1 | 36.12 Billion KRW | 5.95% |
| 2017 Q3 | 37.24 Billion KRW | 1.55% |
| 2016 Q4 | 34.09 Billion KRW | -4.15% |
| 2016 Q3 | 35.57 Billion KRW | -3.12% |
| 2016 Q2 | 36.71 Billion KRW | 4.93% |
| 2016 Q1 | 34.99 Billion KRW | -4.88% |
| 2016 FY | 141.37 Billion KRW | -2.77% |
| 2015 Q4 | 36.78 Billion KRW | -1.04% |
| 2015 FY | 145.39 Billion KRW | 20.45% |
| 2015 Q2 | 36.46 Billion KRW | 4.27% |
| 2015 Q3 | 37.17 Billion KRW | 1.94% |
| 2015 Q1 | 34.97 Billion KRW | 7.17% |
| 2014 Q3 | 30.03 Billion KRW | 1.61% |
| 2014 FY | 120.71 Billion KRW | 15.54% |
| 2014 Q4 | 32.63 Billion KRW | 8.66% |
| 2014 Q2 | 29.55 Billion KRW | 3.75% |
| 2014 Q1 | 28.49 Billion KRW | -1.57% |
| 2013 Q2 | 26 Billion KRW | 11.9% |
| 2013 Q1 | 23.24 Billion KRW | -15.06% |
| 2013 FY | 104.47 Billion KRW | -2.56% |
| 2013 Q4 | 28.94 Billion KRW | 10.11% |
| 2013 Q3 | 26.28 Billion KRW | 1.07% |
| 2012 Q1 | 24.71 Billion KRW | -10.49% |
| 2012 Q2 | 27.62 Billion KRW | 11.78% |
| 2012 Q3 | 27.51 Billion KRW | -0.39% |
| 2012 FY | 107.22 Billion KRW | -2.57% |
| 2012 Q4 | 27.36 Billion KRW | -0.56% |
| 2011 FY | 110.05 Billion KRW | 4.13% |
| 2011 Q2 | 26.99 Billion KRW | -1.35% |
| 2011 Q4 | 27.61 Billion KRW | -1.68% |
| 2011 Q1 | 27.36 Billion KRW | 1.52% |
| 2011 Q3 | 28.08 Billion KRW | 4.02% |
| 2010 Q2 | 26.66 Billion KRW | 2.92% |
| 2010 FY | 105.68 Billion KRW | 6.34% |
| 2010 Q4 | 26.95 Billion KRW | 3.0% |
| 2010 Q3 | 26.16 Billion KRW | -1.85% |
| 2010 Q1 | 25.9 Billion KRW | 9.9% |
| 2009 Q1 | 25.74 Billion KRW | 7.53% |
| 2009 FY | 99.38 Billion KRW | 6.96% |
| 2009 Q3 | 25.47 Billion KRW | 3.54% |
| 2009 Q2 | 24.59 Billion KRW | -4.46% |
| 2009 Q4 | 23.57 Billion KRW | -7.46% |
| 2008 FY | 92.91 Billion KRW | 16.01% |
| 2008 Q1 | 22.72 Billion KRW | 9.49% |
| 2008 Q2 | 22.01 Billion KRW | -3.13% |
| 2008 Q3 | 24.22 Billion KRW | 10.03% |
| 2008 Q4 | 23.94 Billion KRW | -1.16% |
| 2007 Q4 | 20.75 Billion KRW | 0.62% |
| 2007 Q1 | 18.86 Billion KRW | 0.0% |
| 2007 Q2 | 19.83 Billion KRW | 5.15% |
| 2007 FY | 80.09 Billion KRW | 0.0% |
| 2007 Q3 | 20.62 Billion KRW | 3.99% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -67.914% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 79.647% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 63.913% |
| HANDOK Inc. | 522.74 Billion KRW | 55.926% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -70.192% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.606% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 65.301% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -343.448% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 84.547% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -70.776% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 37.822% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -160.057% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -35.871% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -2.645% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -67.914% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -195.175% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -52.507% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -163.718% |
| JW Holdings Corporation | 928.07 Billion KRW | 75.175% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 61.65% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 86.199% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 69.22% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -15.065% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -27.456% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -17.341% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 68.283% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -67.914% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 84.787% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 83.248% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 69.22% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.606% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 71.009% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 1.919% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 61.25% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 69.22% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 21.133% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 17.405% |
| CKD Bio Corp. | 160.35 Billion KRW | -43.679% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 56.278% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 36.198% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -15.065% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 73.812% |
| Boryung Corporation | 859.62 Billion KRW | 73.198% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -82.956% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 37.822% |
| JW Lifescience Corporation | 206.86 Billion KRW | -11.376% |